{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04497987: Phase 3 Interventional Completed COVID-19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:resugosbart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04381936: Phase 3 Interventional Recruiting Severe Acute Respiratory Syndrome
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04381936: Phase 3 Interventional Recruiting Severe Acute Respiratory Syndrome
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02040844: Phase 3 Interventional Completed Cat Allergy
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegtarazimod [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:recaticimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04718389: Phase 3 Interventional Active, not recruiting Asthma
(2021)
Source URL:
Class:
PROTEIN